Lv4
524 积分 2024-07-24 加入
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
14小时前
已完结
Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1
15小时前
已完结
赛恺泽说明书
19天前
已关闭
Pooled Rate of Pseudoprogression, Patterns of Response, and Tumor Burden Analysis in Patients Undergoing Immunotherapy Oncologic Trials for Different Malignancies
25天前
已关闭
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
25天前
已完结
肿瘤免疫治疗疗效评价标准——iRECIST解读
1个月前
已完结
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
1个月前
已完结
新时期研究者发起的临床研究管理实践
1个月前
已完结
皖公网安备34019202002308
